ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 254 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $13,000 | -87.0% | 325 | -82.8% | 0.00% | – |
Q3 2022 | $100,000 | +14.9% | 1,887 | -23.5% | 0.00% | – |
Q2 2022 | $87,000 | -23.7% | 2,468 | 0.0% | 0.00% | – |
Q1 2022 | $114,000 | -95.2% | 2,468 | -93.0% | 0.00% | -100.0% |
Q4 2021 | $2,351,000 | +7.8% | 35,450 | +1.4% | 0.00% | 0.0% |
Q3 2021 | $2,181,000 | -57.5% | 34,945 | -43.6% | 0.00% | -50.0% |
Q2 2021 | $5,131,000 | +63.6% | 61,954 | +31.0% | 0.00% | 0.0% |
Q1 2021 | $3,137,000 | -26.7% | 47,311 | -15.1% | 0.00% | -33.3% |
Q4 2020 | $4,278,000 | +133.9% | 55,748 | +31.2% | 0.01% | +100.0% |
Q3 2020 | $1,829,000 | -6.8% | 42,484 | -6.5% | 0.00% | 0.0% |
Q2 2020 | $1,963,000 | +88.8% | 45,454 | +25.7% | 0.00% | +50.0% |
Q1 2020 | $1,040,000 | +16.3% | 36,156 | +156.4% | 0.00% | +100.0% |
Q4 2019 | $894,000 | +22250.0% | 14,100 | +6950.0% | 0.00% | – |
Q3 2018 | $4,000 | -97.4% | 200 | -98.2% | 0.00% | – |
Q2 2018 | $151,000 | +22.8% | 11,100 | -66.8% | 0.00% | – |
Q4 2017 | $123,000 | – | 33,400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |